Novo Nordisk has appointed Hanover Communications to help support its public affairs and policy work in the UK during 2015.
The Danish drugmaker is hoping to raise the profile of diabetes amongst political and policy stakeholders. Ultimately, the aim is to secure better access to innovative treatments, particularly in prevention, and thus boost outcomes and reign in soaring NHS costs linked with the disease, which are fast approaching £10 billion a year.
“With the political environment uncertain in an election year and the Five Year Forward View unleashing a new wave of change in the way NHS services are delivered, getting diabetes right should be front of mind for politicians, policymakers and payors,” noted Andrew Harrison, Head of Global Healthcare at Hanover.
Hanover’s appointment follows a successful competitive pitch process undertaken in the last quarter of 2014.
Follow us: @PharmaTimes on Twitter